Xu Liang

Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer: Real-World Outcomes and Treatment Transition Patterns in a Chinese Cohort.

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer: Real-World Outcomes and Treatment Transition Patterns in a Chinese Cohort.

Journal: Current oncology (Toronto, Ont.)
Published: July 07, 2026

Clinicopathological discordance and survival outcomes in 154 breast cancer patients with pulmonary metastasis in a real-world setting.

Clinicopathological discordance and survival outcomes in 154 breast cancer patients with pulmonary metastasis in a real-world setting.

Journal: Discover oncology
Published: February 16, 2026

Progress of Trop-2-targeted antibody-drug conjugates in HER-2-negative breast cancer: a mini-review.

Progress of Trop-2-targeted antibody-drug conjugates in HER-2-negative breast cancer: a mini-review.

Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer
Published: December 05, 2025

Real-World Study on the Efficacy and Safety of Incadronate Disodium in Treating Bone Metastases of Advanced Breast Cancer.

Real-World Study on the Efficacy and Safety of Incadronate Disodium in Treating Bone Metastases of Advanced Breast Cancer.

Journal: Current pharmaceutical design
Published: September 17, 2025

Al 18 F-NOTA-HER2-BCH Versus 18 F-FDG PET/CT for Detecting Bone Metastases : Sensitivity and Quantitative Comparison.

Al 18 F-NOTA-HER2-BCH Versus 18 F-FDG PET/CT for Detecting Bone Metastases : Sensitivity and Quantitative Comparison.

Journal: Clinical nuclear medicine
Published: July 21, 2025

Long-term survival outcomes and subtype variations between primary breast cancer and liver metastases in 542 patients with advanced breast cancer: insights from a real-world analysis.

Long-term survival outcomes and subtype variations between primary breast cancer and liver metastases in 542 patients with advanced breast cancer: insights from a real-world analysis.

Journal: Discover oncology
Published: May 12, 2025

Al18F-NOTA-HER2-BCH versus 18F-FDG PET/CT in evaluating newly diagnosed HER2-low breast cancer patients.

Al18F-NOTA-HER2-BCH versus 18F-FDG PET/CT in evaluating newly diagnosed HER2-low breast cancer patients.

Journal: European journal of nuclear medicine and molecular imaging
Published: November 28, 2024

Phase I trial of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors.

Phase I trial of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors.

Journal: The oncologist
Published: October 18, 2024

Real-world outcomes of first-line treatment with HLX02 versus reference trastuzumab plus pertuzumab in HER2-positive metastatic breast cancer.

Real-world outcomes of first-line treatment with HLX02 versus reference trastuzumab plus pertuzumab in HER2-positive metastatic breast cancer.

Journal: The oncologist
Published: July 20, 2024

HER2 status results in an unstable switch from primary to recurrent breast cancer.

HER2 status results in an unstable switch from primary to recurrent breast cancer.

Journal: Neoplasma
Published: February 29, 2024

Impact of HER2-targeted PET/CT imaging in patients with breast cancer and therapeutic response monitoring.

Impact of HER2-targeted PET/CT imaging in patients with breast cancer and therapeutic response monitoring.

Journal: The oncologist
Published: December 05, 2023

Real-world study of palbociclib combined with endocrine therapy for patients with metastatic breast cancer: A comparison of subsequent treatment patterns and HER2 expression analysis.

Real-world study of palbociclib combined with endocrine therapy for patients with metastatic breast cancer: A comparison of subsequent treatment patterns and HER2 expression analysis.

Journal: Cancer
Published: September 12, 2023
Showing 1-12 of 35

Last Updated: 09/26/2026